Insulin biosimilars Market Report 2026

The insulin biosimilars market size has grown rapidly in recent years. It will grow from $3.5 billion in 2025 to $4.02 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to rising prevalence of diabetes, high cost of originator insulin, increasing awareness about biosimilars, patent expiry of reference insulin products, government initiatives to promote biosimilars.

The insulin biosimilars market size is expected to see rapid growth in the next few years. It will grow to $6.89 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to technological advancements in biosimilar production, expansion of healthcare infrastructure, supportive regulatory frameworks, growing telemedicine adoption, increasing demand in emerging markets. Major trends in the forecast period include increasing adoption of biosimilar insulins, rising incidence of diabetes globally, cost-effective diabetes management solutions, growth of online and retail pharmacy channels, enhanced focus on patient-centric care.

The rising prevalence of diabetes is anticipated to drive the growth of the insulin biosimilars market in the coming years. Diabetes is a group of chronic metabolic conditions marked by persistently elevated blood glucose levels. Insulin biosimilars are increasingly important in diabetes management because they offer cost-effective alternatives to branded insulin therapies. As the number of individuals living with diabetes continues to grow, demand for affordable and accessible insulin options is increasing, thereby supporting market expansion. For example, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the proportion of people with type 1 diabetes receiving all eight recommended care processes rose by 22%, while for type 2 diabetes it increased by 21%. In addition, the percentage of individuals achieving target HbA1c levels climbed to 37.9%, the highest level ever reported by the National Diabetes Audit. Therefore, the growing prevalence and improved management of diabetes are contributing to the expansion of the insulin biosimilars market.

Major companies operating in the insulin biosimilars market are increasingly entering into strategic partnerships to develop new products and reinforce their market positions. Strategic partnerships involve collaboration between organizations to combine complementary strengths, share resources, and achieve common business goals. For instance, in September 2023, Meitheal Pharmaceuticals, Inc., a US-based pharmaceutical company, partnered with Tonghua Dongbao Pharmaceutical Co. Ltd., a China-based active pharmaceutical ingredient manufacturer, to commercialize three insulin biosimilars, including insulin lispro, insulin glargine, and insulin aspart. Through this collaboration, Meitheal Pharmaceuticals aims to broaden its product portfolio and enhance its international presence in the insulin biosimilars market.

In September 2023, Meitheal Pharmaceuticals, Inc. also entered into an exclusive licensing agreement with Tonghua Dongbao Pharmaceutical Co. Ltd. to commercialize three insulin biosimilars - insulin aspart, insulin lispro, and insulin glargine - in the United States. Under this agreement, Meitheal secured future US marketing rights for these products, subject to approval by the U.S. Food and Drug Administration. This partnership is intended to strengthen Meitheal’s position in the US insulin biosimilars market while supporting improved affordability and access to insulin therapies. Tonghua Dongbao Pharmaceutical is a China-based biopharmaceutical manufacturer specializing in the development and production of insulin and other endocrine-related biosimilar products.

Major companies operating in the insulin biosimilars market are Eli Lilly and Company, Biocon Ltd., Mylan N.V., NOVO Nordisk A/S, Sanofi S.A, Sandoz International GmbH, Dr. Reddy's Laboratories Ltd., Samsungbioepis Co. Ltd., Teva Pharmaceutical Industries Ltd., Stada Arzneimittel AG, Celltrion Inc., Fujifilm Kyowa Kirin Biologics Co. Ltd., Green Cross Corporation, Aurobindo Pharma Ltd., Intas Pharmaceuticals Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Lifescience Ltd., Boehringer Ingelheim GmbH, Wockhardt Limited, Cadila Pharmaceuticals Ltd.

North America was the largest region in the insulin biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global insulin biosimilars market report during the forecast period. The regions covered in the insulin biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the insulin biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the insulin biosimilars market by increasing the cost of imported active pharmaceutical ingredients (APIs) and manufacturing equipment, leading to higher production costs. This impact is particularly significant in segments such as rapid-acting and long-acting biosimilars, with Asia-Pacific regions like China and India being most affected due to their role as major suppliers. While tariffs pose challenges, they also incentivize local production and investment in domestic manufacturing, potentially strengthening regional supply chains and fostering innovation in cost-effective biosimilar solutions.

The insulin biosimilars market research report is one of a series of new reports that provides insulin biosimilars market statistics, including insulin biosimilars industry global market size, regional shares, competitors with a insulin biosimilars market share, detailed insulin biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the insulin biosimilars industry. This insulin biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Insulin biosimilars are biological products that are comparable in quality, safety, and effectiveness to an already approved and marketed reference insulin product. They are widely used to regulate blood glucose levels and are essential for individuals with diabetes to maintain healthy glucose control.

The main biosimilar types of insulin biosimilars include rapid-acting biosimilars, long-acting biosimilars, and premixed-acting biosimilars. Rapid-acting biosimilars are a category of biosimilar insulin products formulated to provide a quick onset of action with a relatively short duration of effect. These products are used for disease indications such as type I diabetes and type II diabetes and are distributed through channels including hospital pharmacies, retail pharmacies, and online pharmacies. They are utilized by various end users such as hospitals, ambulatory surgical centers, and other healthcare facilities.

The insulin biosimilar market consists of sales of a variety of insulin types such as intermediate insulin, insulin glargine, and insulin analog. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.